Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
If your copay is too high, your GLP-1 isnt covered, or youre uninsured, GoodRx details several options to help make your prescription more affordable in the table below
PubMed laboratory research record [PMID: 37449929] PubMed record related to this compound for laboratory literature review
Most GLP peptides fall between 99.4% and 99.9%, depending on the peptide chain length
A GLP-1 receptor agonist that helps regulate blood sugar levels and promote weight loss
